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Does biological understanding influence surgical practice?
R. Blamey
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The short answer to the question that has been posed, taking
the practice generally, is 'no'; since this would result in a
lecture commendable for accuracy but remarkable for
brevity I am going to take the liberty of slightly amending
the title to 'Will biological understanding influence clinical
practice?' I will use breast cancer as my example. Treatments
are not at present carried out on a strictly scientific basis;
rather they have come from a process of amending history.
Nevertheless, the past 30 years has seen considerable
movement on surgery towards this desirable end. Surgery
until the 1960s followed a generally unscientific attitude
towards breast cancer: perhaps I am a little unfair on my
predecessors, for to follow a scientific path depends upon the
contemporary view and this is influenced by the
predominant medical science of the day.
The era of the anatomist
In the 1880s anatomy was the predominant science. Breast
cancer was treated by a mutilating and sometimes fatal
operation. Since there was no microscopic diagnosis,
operation was often left until the cancer, by today's
standards, was locally advanced, with the consequence that
local recurrence on the chest wall was common. At this time
Halsted at Johns Hopkins Hospital introduced his radical
mastectomy. He showed that he had reduced the incidence
of local recurrence from somewhere around 50% to around
5% and on this basis the treatment of breast cancer for the
next 60 years became wide local ablation of the primary
growth.
This, at the time, must have seemed a reasonable scientific
deduction from Halsted's work but this incidence would
have declined in any case. Surgery was being carried out at
an earlier stage because of the introduction of histological
diagnosis and because better anaesthetic procedures had
lowered the risks.
Halsted had removed the axillary chain of lymph nodes.
With morbid anatomy now coming to first place among
medical sciences, the observation that breast cancers often
invaded the draining lymph nodes led to the reasonable
supposition, most strongly expressed by Sampson Handley
(1922) at the Middlesex Hospital, that breast cancers spread
through the lymphatic system. The extensive local surgery
now became reinforced by irradiation of skin flaps and
lymph node areas.
This was the general message imparted to medical students
as late as the 1970s: 'cancers spread through the lymph
nodes'; therefore there was a stage at which cure could result
from treatment of the nodes; therefore wide local surgery
and en bloc removal of the nodes was the correct treatment.
The era of clinical trials
The doctrine of extensive local surgery began to be
challenged in the 1950s by workers such as Paterson in
Manchester and consequently the most influential science
became that of clinical trials.
The Christie Hospital trial (Simpson, 1986) questioned
whether radiotherapy was required in addition to surgery. A
series of trials comparing treatments of primary breast
cancer finally culminated in the Cancer Research Campaign
trial (Haybittle et al., 1989) which demonstrates, now to 17
years of follow-up, that there is no survival advantage to
more aggressive treatments than removal of the breast alone.
Indeed both this trial and Paterson's trial demonstrate a
long-term hazard from radiotherapy.
The trials also provided excellent long-term follow-up of
breast cancer cases which gave a better understanding of the
prognosis in breast cancer. Brinkley and Haybittle (1975)
followed 704 cases of breast cancer treated by mastectomy
and lymph node removal or irradiation. Despite this
adequacy of local treatment the chance of survival 20-25
years after mastectomy was only around 20%, even in stage
I and stage II cases. If the lymph nodes were shown to be
involved at histology then long-term survival was even
worse, demonstrating the previous illogicalities of node
clearance and irradiation: if the nodes were involved radical
treatment did not help, if they were not involved it was not
needed. If most women with breast cancer ultimately die of
the disease and yet the primary is controlled, then they must
have distant metastases present at the time of diagnosis.
We now had a new view of breast cancer - that prognosis
depended not on treatment of the primary growth but on
whether metastases were present or not. The philosophy of
extensive local treatment could no longer be upheld.
Furthermore, the principal route of spread was via the
bloodstream and lymph node invasion acted simply as a
marker of spread.
The era of the oncologist
The recognition that metastases were often present from an
early stage gave rise to the idea that systemic treatment
should be applied as early as possible. In favour of this was
experimental research which had shown that the smaller the
tumour the better the results from cytotoxic therapy. The
counter argument was that if therapy diminishes the number
of cancer cells by 10- or 100-fold and regrowth is linear, then
the remission produced will be the same length whether
therapy is given early or later.
To demonstrate a small benefit in human trials is very
difficult. It required Peto (Early Breast Cancer Trialists'
Collaboratory Group, 1988) to assemble and analyse the
whole world expertise in order to have enough patients to
give statistical confidence; this done, a small effect in favour
of adjuvant therapy, whether cytotoxic or hormonal, was
shown.
Problems of clinical trials
The problem with the results of clinical trials is that they
give an overall answer. This would be useful if breast cancers
arrived uniformly and responded to treatments uniformly.
The trials discussed above suggest: (1) that prophylactic
lymph node treatment carries no advantage overall. Does
this mean that no patients would benefit from this
treatment? (2) That adjuvant hormonal therapy is beneficial.
Does this mean that all patients would benefit?
To examine the first of these questions, we have shown
that patients who are shown to have lymph node invasion at
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node sampling, and together with this have poorly
differentiated tumours, have a 60% chance of requiring
subsequent radiotherapy to the wound flaps or axilla over a
five-year period (Williams et al., 1985). This group is a
minority but these individuals would benefit from
prophylactic treatment to the lymph nodes.
The second question regards adjuvant hormone therapy.
Some tumours do not have the biological capacity to
respond to hormone treatments. Once we are confident of
the accuracy of assays which predict clinical effect, then it
will become standard not to give adjuvant hormone therapy
to unresponsive tumours.
In other words, the challenge we now face is to define the
individual nature of the breast cancer in each patient, rather
than consider any one treatment as suitable for all tumours.
This is where tumour biology has become the dominant
science.
The era of the tumour biologist
Oestrogen receptor was the earliest biological measurement
to be introduced into clinical practice. ER unfortunately
proved of less clinical value than was initially hoped. Sixty
per cent of tumours with high levels of receptor respond to
hormone therapy but so do some 10% of oestrogen receptor
negative patients in many series. With no alternative
treatments available that did not carry side-effects, and with
a 10% chance of success at the worst prediction, hormone
therapy continued to be applied to all patients with
advanced disease.
The importance of the description of ER was not in its
direct use but that it was the first biological measurement
which was widely recognised to relate to aspects of tumour
behaviour (Williams et al., 1987), in the prediction of
response, in relation to histological differentiation, and in its
relation to prognosis where, as might be expected, its main
effect lies during the phase of treatment of advanced disease.
Prediction of prognosis
The requirement to predict the behaviour of each individual
tumour in order to institute the correct course of treatment
is how we came to the era of the tumour biologist.
Individuality may be expressed as prognosis, tissue of
metastases and sensitivity to therapies.
The prognosis of a breast cancer depends upon two sets of
factors, one time-dependent, the other set intrinsic to the
tumour (the biological factors).
The time-dependent factors are tumour size and lymph
node stage. In Nottingham tumours are staged by node
sampling and considerable differences in survival between
tumours with no node involvement, low node involvement
and high node involvement can be demonstrated (Todd et
al., 1987). The biological factors which influence the tumour
are numerous but their combined effect is expressed as
histological differentiation and again considerable differences
can be shown between survival in well differentiated,
moderately differentiated and poorly differentiated tumours.
Factors may be combined together to create an accurate
index of prognosis (Todd et al., 1987). Using size, stage and
grade groups of patients may be defin.ed in one of which the
chance of survival is only 10% at five years and in another
of which a group with a life expectancy greater than 80% at
12 years is defined (Figure 1). This latter group is
statistically inseparable from an age-matched group of
women without breast cancer at all and represents a 'cured'
group.
This has direct clinical application, for if a patient has no
greater chance of death than a woman without breast cancer,
then she does not need adjuvant therapy and around a
quarter to one-fifth of our patients at the present time are
thereby excluded from this need.
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Figure 1
There are other clinical applications of biological factors
for the treatment of primary tumour. Treatment by excision
and irradiation is being used for many women. The majority
are treated satisfactorily but around 20% suffer recurrence in
the treated breast which may then be impossible to control.
The treatment is much safer to recommend once this group
are recognised and based on our experience they can be
selected by the combination of their size and whether they
have the histological feature of vascular invasion in the
tumour, especially in patients who are young (Locker et al.,
1989).
Biological factors and the growth of breast cancers
These are examples of where the definition of the individual
nature of the tumour strongly influences therapy. In this
definition of individuality I have several times referred to
histological grade. What makes a tumour well or poorly
differentiated? Ultimately the structure of the DNA,
translated through growth factors and other factors. Several
such factors have been examined in Nottingham.
NCRC-11 is a monoclonal antibody made by Adrian
Robins at the Cancer Research Campaign laboratories in
Nottingham to a breast cancer. The antigen is expressed on
epithelial surfaces and we have shown that its expression in
breast cancer relates to grade and to prognosis (Ellis et al.,
1987). Similarly the binding of the lectin helix promatia to
breast cancer cells relates to prognosis (Fenton et al., 1987).
Tumour ploidy measured by flow cytometry relates to
prognosis and, we have shown by karyotyping to the degree of
chromosomal abnormality. Epidermal growth factor receptor
status inversely correlates with ER status and both relate to
prognosis, although in our series their combination is still
not as powerful as histological grade. The monoclonal
antibody Ki67 is taken up by cells in division and its uptake
relates to grade and to prognosis. The S-phase calculated
from flow cytometry can be similarly used as can the
calculated proliferative index. The oncogene product c-myc,
shown using the antibody of Dr Evans (Cambridge), relates
to prognosis (Dowle et al., 1987) although in our series the
oncogene ErB2 (using the antibody of Dr Gullick,
Hammersmith Hospital) does not have a strong relation to
prognosis. These are all of great interest and will eventually
each show us a different aspect of tumour behaviour (for
example, erbB2 in borderline lesions; see below).
None are as powerful prognostically as histological grade;
how then may they be used at present to improve prognostic
discrimination? First, histological grade is an excellent factor
in the hands of an expert pathologist. However, it is
subjective and there are not many specialist pathologists in
the breast cancer field. A technical officer making objective
measurements using flow or image analysis would be ideal
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been achieved in Nottingham by Ellis and Bell using a
combination of Ki67 and a cell morphometric measurement.
Several other measurements of proliferation could be added
or substituted; Locker has shown in our series that
proliferative index appears promising in this respect.
Diagnosis
In tumour diagnosis, we have shown that a combination of
cell size, Ki67 and DNA ploidy measured on cytological
aspirates in the Becton Dickinson CAS 100 system gives very
accurate diagnostic information.
It is nearly within our grasp to be able to take cells from a
tumour by fine needle aspiration and to use these to give
diagnosis, predict prognosis, and predict the likely site of
metastasis (Campbell et al., 1981) and the sensitivity to
hormone manipulation. There are already methods proposed
which may be added and will indicate sensitivity to
individual chemotherapeutic agents and to radiotherapy.
Armed with this information we will then be able to
individualise treatments depending upon need and upon
sensitivity.
Definition of borderline lesions
Tumour biology will also make a mark in the very early
stages and in advanced disease. Breast cancer screening has
been shown to cut mortality from breast cancer (DHSS,
1986). Screening programmes are bringing to light large
numbers of lesions in the borderline between being a risk
factor or a developed cancer. The histological diagnosis of
these lesions is difficult and the borders are not precise. The
final changes defining the borderline of malignancy will have
to come from gene analysis. Gullick has shown that erbB2
expression is higher in comedo in situ cancers and these
appear to have the highest malignant potential of the in situ
lesions (Gullick et al., 1989). In Nottingham, Parkin and
Gilmour have studied a small group of breast cancers by
genetic fingerprinting and found that the majority differ
from their somatic patterns, whereas benign lesions do not.
Advanced disease
In the treatment of advanced disease decisions regarding
change of therapy are based on clinical judgement. Ideally
we required a tumour serum marker to allow, objective
evaluation of tumour regression or progression. In advanced
breast cancer we have shown that by using a combination of
established markers (CEA, ESR, CRP, ferritin and
orosomucoid; Williams et al., 1989) - each only used when it
is at a very high level, that is above the level of 95% of sera
from patients with primary tumours - good sensitivity and
specificity for tumour stability or progression can be
achieved.
We have since found that the monoclonal antibody CA 15-
3 used with CEA and ESR appears even more promising. I
believe that in the near future we will be able to achieve
better results from therapy in advanced disease by using
these serum markers to guide treatment objectively.
In conclusion I hope I have been able to illustrate that we
are moving into an era where clinicians will use biological
measurements to decide upon the best treatment for each
individual tumour.
A primary breast cancer resembles a coded message in
which is written the whole of the future clinical behaviour of
the tumour and the prognosis of the woman. We will be able
to decode this by automated means and select the
appropriate treatment.
The challenge for the.clinician is to translate the biological
findings into usable measurements. To effect this translation
does require very large series of patients, carefully studied by
clinical staff with identified time to carry out this task;
herein lies a message to the research funding bodies. There is
no point in reporting measurements of serum markers or
prognostic factors (the journals are full of such reports)
unless they can be shown to be both clinically usable and
superior to any other measurements for that use.
There are many challenges for the biologist and I list some
in breast cancer: (1) A model of breast cancer growth
showing total mass of cancer in the body and its rate of
increase. Survival times in women with large primary
tumours are many years shorter than with smaller tumours
yet it only takes around six months to one year to grow
from a small to a large primary tumour. Tumour mass in the
body therefore appears to increase geometrically and not
logarithmically. (2) Knowledge of how metastasis occurs.
Are specific factors needed to make it happen and can they
be blocked? (3) The genetic structure which defines the
borderline of cancer. (4) The action of cytotoxic agents on
the DNA. (5) The cellular mechanisms of acquired resistance
to treatments.
For those in the research laboratory I leave the satisfying
message that biological measurements will shortly be of great
clinical use in the treatment of breast cancer. Your discipline
- tumour biology - is at present the predominant science
influencing how we look at breast cancer, but beware, the
geneticists are at your shoulder.
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